Through exclusive licenses from J. Doudna and C.Castro, DNA Nanobots folds target genes to be their own gene delivery system. We have developed a portfolio of non-viral, DNA-based genobots which can deliver significantly larger genes (up to 15 kb) with little/no immunogenicity (multiple dosing), with less off-target toxicity at lower cost thus allowing access by larger patient populations than current expensive gene therapeutics.